Outlook Therapeutics, Inc. (OTLK)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 86/100 (CRITICAL), 2.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 30.53% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
- Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
- Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet
- Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
- Why Did OTLK Stock Crash In Pre-Market Today?
- Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
- OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
- Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Outlook Therapeutics, Inc..
Full OTLK Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.